Affiliation:
1. Institute of Experimental Immunology, Department of Inflammation Research, University of Zurich, Zurich, Switzerland
Abstract
Chronic inflammatory diseases like psoriasis, Crohn’s disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly recognized as disease entities, where dysregulated cytokines contribute substantially to tissue-specific inflammation. A dysregulation in the IL-23/IL-17 axis can lead to inflammation of barrier tissues, whereas its role in internal organ inflammation remains less clear. Here we discuss the most recent developments in targeting IL-17 for the treatment of chronic inflammation in preclinical models and in patients afflicted with chronic inflammatory diseases.
Funder
Swiss National Science Foundation
European Union FP7 Project ATECT
European Union H2020 Project IPC
University Research Priority Project Translational Cancer Research
Publisher
Rockefeller University Press
Subject
Immunology,Immunology and Allergy
Reference202 articles.
1. Inflammatory bowel disease;Abraham;N. Engl. J. Med.,2009
2. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17;Aggarwal;J. Biol. Chem.,2003
3. Interleukin-23 drives intestinal inflammation through direct activity on T cells;Ahern;Immunity.,2010
4. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation;Akimzhanov;J. Biol. Chem.,2007
5. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha;Albanesi;J. Immunol.,1999
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献